Project Grant R21EY039061
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded a $3.05M Project Grant to Doheny Eye Institute effective September 1, 2025, through August 31, 2028, under the Vision Research program (CFDA 93.867). This research project will deliver scientific findings and mechanistic insights regarding the role of mechanobiology in retinal vascular inflammation and degeneration associated with diabetic retinopathy (DR). The project focuses on identifying how diabetes-induced retinal...
- Federal Grant Award Summary The National Eye Institute (Vision Research program, CFDA 93.867) awarded The Leland Stanford Junior University a $3.57 million Project Grant on September 15, 2025, for the "Integrated Molecular Profiling of Diabetic Retinopathy" research initiative, with a completion date of August 31, 2028. The award supports the development and application of TEMPO (Tracing Expression of Multiple Protein Origins), an innovative proteomics platform that integrates...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $638,625 Project Grant to the University of California, San Diego, effective August 1, 2025 through July 31, 2028, under the Vision Research program (CFDA 93.867). The award funds research to investigate the mechanisms of drusen formation in age-related macular degeneration (AMD), a leading cause of blindness affecting approximately 196 million people globally. The research employs a novel quartz crystal microbalance assay...
- Grant Award Summary The University of Pennsylvania received a $1.18M Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded September 1, 2025, with completion anticipated by April 30, 2030. This research project, titled "Characterizing Photoreceptor Precursor Cells for Retinal Transplantation," will deliver scientific findings and methodological advances addressing low integration rates in cell-based therapies for retinal...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded $173,016 to the Whitehead Institute for Biomedical Research under the Vision Research program (CFDA 93.867) for a project grant effective August 1, 2025, through July 31, 2027. This award supports systematic identification and mechanistic characterization of novel oxidative protective genes to prevent retinal pigment epithelium (RPE) degeneration in age-related macular degeneration (AMD). The research involves...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $617,244 Project Grant to the University of North Carolina at Charlotte, effective May 1, 2026 through March 31, 2030, under the Vision Research program (CFDA 93.867). This award supports the development of distributed foundational machine learning (ML) models for diabetic retinopathy (DR) diagnosis, prognosis, and treatment outcome assessment using multi-modal optical coherence tomography (OCT) imaging data. The primary...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded The Ohio State University $413,478 on September 22, 2025, to develop and test a novel adeno-associated virus (AAV) delivery approach for treating inherited retinal diseases (IRDs). The primary deliverable is research establishing an insulin-accelerated, pre-retinal gene therapy methodology that addresses significant clinical limitations of existing subretinal AAV...
- Summary of Federal Project Grant Award The National Eye Institute (NEI) awarded a $422,125 Project Grant to the University of Miami's Office of Research Administration—School of Medicine on August 1, 2025, under the Vision Research program (CFDA 93.867) for a two-year project period concluding July 31, 2027. This award funds research investigating cholesterol homeostasis as a therapeutic target for demyelinating eye diseases, which are pathologies affecting the optic nerve that can cause...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded Indiana University a $498,000 Project Grant on September 15, 2025, for research extending through August 31, 2028. The research, titled "The Contribution of Plasticity to the Recovery of Retinal Function Following Gene Therapy," will deliver fundamental scientific knowledge regarding how the retina responds to gene therapy treatments for inherited retinal...
- Federal Grant Award Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a $615,928 Project Grant effective April 15, 2026, with completion targeted for March 31, 2030. This award funds research investigating the mechanobiology of Bruch's membrane during aging and its implications for age-related macular degeneration (AMD), a leading cause of blindness in elderly...
The National Eye Institute (NEI) awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, a Project Grant of $430,650 under the Vision Research program (CFDA 93.867) for the period June 1, 2026 through May 31, 2028. This R21 Exploratory/Developmental Research Grant funds innovative research investigating the molecular mechanisms linking diabetic nephropathy (kidney disease) and diabetic retinopathy (DR), a leading cause of blindness in individuals with diabetes. The research examines the role of the stress response protein REDD1 (Regulated in Development and DNA Damage 1) in both retinal and renal dysfunction, with the ultimate goal of identifying preventative therapeutic strategies targeting early-stage disease pathogenesis rather than relying solely on current treatment approaches such as intraocular VEGF (Vascular Endothelial Growth Factor) inhibition. The research deliverables will advance understanding of the systemic molecular events contributing to DR pathogenesis by exploring an unexpected finding that kidney-specific REDD1 deletion prevented diabetes-induced functional deficits in both the retina and kidney. These studies are designed to reframe the current understanding of the renal-retinal axis in diabetes and potentially identify novel intervention targets in the preclinical and non-proliferative stages of diabetic retinopathy, addressing a significant unmet clinical need for more effective preventative treatment strategies.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $430.7k | 6/3/26 |